Theranostics economics: how PSMA and DOTATATE are reshaping nuclear medicine reimbursement

Theranostic radiopharmaceuticals are creating new procedure code volumes and ownership opportunities. Here’s the rate data and the operator economics.

The arrival of Lutetium-177 (Lu-177) PSMA and DOTATATE therapies has fundamentally altered the strategic landscape for nuclear medicine practices. For years, our specialty has been primarily diagnostic, with reimbursement tied to reads and scans. Theranostics changes the model entirely, introducing high-value, longitudinal therapeutic procedures that create entirely new service lines. This isn’t just a clinical evolution; it’s a financial one, opening the door for physicians to build and own the sites where this care is delivered.

But capturing this opportunity requires a different kind of thinking. It demands a shift from the W-2 employee mindset to that of a business owner, fluent in the language of pro formas, capital expenditures, and sophisticated tax strategy. The economics are compelling, but only if you structure the venture correctly from day one. We’ll break down the reimbursement data for these key procedures and then walk through the specific tax and operational structures that successful physician-owners are using to build wealth. For a broader look at the tools and calculators relevant to our field, you can explore the nuclear medicine free tools hub.

The New Reimbursement Powerhouses: PSMA and DOTATATE by the Numbers

The financial viability of a theranostics service line hinges on understanding the reimbursement for both the diagnostic imaging and the therapeutic infusions. These are not low-volume, low-margin procedures. They represent a significant revenue opportunity, particularly in an outpatient setting where operators can capture both the professional and technical fees.

Let’s look at the key codes:

* **Diagnostic Imaging:** Ga-68 DOTATATE (A9587) and Ga-68 PSMA-11 (A9597) PET scans are the gateways to therapy. Reimbursement for these scans is robust, often ranging from $3,000 to $5,000 globally, depending on the payer and geography. This is the initial, recurring revenue stream that identifies patients for treatment.
* **Therapeutic Infusion:** The real economic shift comes from the therapy itself. Lutetium Lu-177 dotatate (Lutathera) uses HCPCS code A9513. The drug cost is significant, but the total reimbursement for the drug and its administration (CPT 77750, complex clinical brachytherapy) can be substantial.
* **PSMA Therapy:** Similarly, Lutetium Lu-177 vipivotide tetraxetan (Pluvicto) uses HCPCS code A9602. A full course of treatment involves up to six infusions. The all-in reimbursement per infusion, including the radiopharmaceutical and administration, often falls in the $40,000 to $50,000 range. A single patient completing a full course of therapy can therefore represent over $200,000 in revenue for the center.

When you’re building a pro forma for a new theranostics center, these numbers are the foundation. However, national averages are just a starting point. Your actual contracted rates with commercial payers will determine your profitability. Most of us learned the hard way that just accepting the first offer from a payer is a recipe for leaving tens of thousands of dollars on the table per case. Modeling your specific market requires real-world data. This is where having access to granular, procedure-specific benchmarks becomes critical for negotiating contracts and verifying the financial feasibility of your plan. You can see how this plays out with CenterIQ procedure rate data, which helps operators model revenue based on local payer contracts.

Owning the Facility: The Economics of an Outpatient Theranostics Center

The revenue from PSMA and DOTATATE therapies is compelling enough to justify bringing them out of the hospital and into a physician-owned outpatient center. This model allows the physician group to capture the facility fee, which is where the majority of the profit resides. However, this path involves significant capital investment and operational complexity.

An outpatient theranostics center is essentially a specialized imaging center combined with an infusion suite. The startup costs include:
* **PET/CT Scanner:** $1.5M – $2.5M
* **Hot Lab & Infusion Suite Build-out:** $500k – $1M+ (including lead shielding, specialized HVAC, dose calibrators, and patient amenities)
* **Licensing and Accreditation:** Significant costs for state licenses, RAM licenses, and accreditation bodies.

The ownership structure is typically an LLC or partnership, where physician-investors contribute capital and receive ownership equity. The center generates revenue, pays its operating expenses (staff, rent, supplies, drug costs), and distributes the remaining profit to the owners via a K-1.

This K-1 income is where the real financial planning begins. Unlike a W-2 salary, K-1 income comes with pass-through deductions, particularly depreciation, which can create enormous tax savings in the early years. For instance, the depreciation on a $2M PET/CT scanner can create a massive “paper loss” in the first year, even if the center is cash-flow positive. This loss flows through the K-1 to the physician-owners, directly reducing their taxable income from other sources.

**The Trap:** Many physicians focus solely on the potential profit distributions and underestimate the operational hurdles. Running a nuclear medicine facility requires dedicated management, complex supply chain logistics for radiopharmaceuticals, and rigorous regulatory compliance. Before committing capital, it’s crucial to conduct a thorough feasibility study that models patient volumes, payer mix, and operational costs. A formal ASC/OBL feasibility advisory engagement can pressure-test these assumptions and prevent a catastrophic financial misstep.

Year One Tax Shield: Section 179 and Bonus Depreciation

For physician-owners of a new theranostics center, the most powerful wealth-building tool in the first year is aggressive depreciation. The IRS gives you two primary mechanisms to accelerate these deductions: Section 179 and bonus depreciation.

**Here’s how it works:**

1. **Section 179 Expensing:** This rule allows you to treat the cost of qualifying equipment as an expense rather than a capital asset that you depreciate over many years. For 2026, the maximum Section 179 deduction is $1,160,000. So, on that new $2.5M PET/CT scanner, you can immediately deduct the first $1.16M of its cost.

2. **Bonus Depreciation:** After you’ve used your Section 179 allowance, bonus depreciation lets you deduct a large percentage of the remaining cost in the first year. While the rate is scheduled to phase down, let’s assume for planning it’s at 60% in 2026. On our $2.5M scanner, the remaining cost after the Section 179 deduction is $1,340,000 ($2.5M – $1.16M). You could then take a 60% bonus depreciation deduction on that amount, which is another $804,000.

**The Math:**
* Total Equipment Cost: $2,500,000
* Section 179 Deduction: ($1,160,000)
* Bonus Depreciation (60% of remaining $1.34M): ($804,000)
* **Total Year-One Deduction:** **$1,964,000**

This nearly $2 million deduction is passed through to the physician partners on their K-1s, directly offsetting their clinical income and dramatically reducing their tax liability. This is how you use the tax code to help finance your initial capital outlay.

**The Trap:** The Section 179 deduction has a spending cap. In 2026, it begins to phase out dollar-for-dollar if you place more than $2,900,000 of new equipment in service during the year. If your total CapEx for the center build-out exceeds this, your ability to use Section 179 is reduced or eliminated. This makes careful planning of equipment purchases and timing essential.

Advanced Strategy: The Equipment Leasing Entity for QBI

Most practicing physicians are painfully aware of the Qualified Business Income (QBI) deduction under Section 199A. It allows owners of pass-through businesses to deduct up to 20% of their business income. However, medicine is classified as a “Specified Service Trade or Business” (SSTB), meaning the deduction phases out completely once your taxable income exceeds ~$394,000 (single) or ~$787,000 (joint) in 2026. For most physician-owners, the QBI deduction from their medical practice is zero.

But there’s a structural workaround that can sometimes reclaim it. This involves splitting your operation into two separate legal entities:

1. **PracticeCo (S-Corp or LLC):** This is your clinical practice. It employs the staff, bills for services, and is an SSTB. Its income will not qualify for QBI for high-income owners.
2. **EquipCo (LLC):** This is a separate entity that you and your partners own. EquipCo buys the PET/CT scanner and other major equipment. It then executes a formal, fair-market-value lease agreement to lease that equipment to PracticeCo.

The rental income generated by EquipCo is generally *not* considered SSTB income. Therefore, that income may be eligible for the 20% QBI deduction, even for high-income physicians.

**The How-To Sequence:**
1. Form a separate LLC (EquipCo) with the same ownership structure as the practice.
2. EquipCo obtains financing and purchases the imaging equipment.
3. Draft a legally sound, triple-net (NNN) lease agreement between EquipCo and PracticeCo at a fair market rental rate.
4. PracticeCo makes monthly lease payments to EquipCo.
5. EquipCo passes its net rental income (rent minus expenses like interest on the equipment loan) to the owners on a K-1. This income is potentially QBI-eligible.

**The Trap:** This is not a DIY strategy. The IRS has strict aggregation rules under §1.199A-4 that govern when related entities can be grouped. The entities must have common ownership (50% or more), and there are other requirements. If you set this up incorrectly—for example, if the lease isn’t at a true market rate or the entities are too intertwined—the IRS can disregard the structure and disqualify the QBI deduction. This must be designed and executed with a CPA who has specific experience with these regulations for medical practices.

Maximizing Real Estate Deductions with Cost Segregation

If your group decides to buy or build the building for your theranostics center, you unlock another powerful tax strategy: cost segregation.

Normally, a commercial building is depreciated straight-line over 39 years. A $3M building would give you a depreciation deduction of about $77,000 per year. A cost segregation study is an engineering-based analysis that breaks the building down into its constituent components and reclassifies them into shorter-lived asset classes.

**Here’s how it works:**
* **39-Year Property:** The core building structure (foundation, walls, roof).
* **15-Year Property:** Land improvements (parking lots, landscaping, exterior signage).
* **7-Year Property:** Office furniture and fixtures.
* **5-Year Property:** Specialized components (carpeting, decorative lighting, dedicated electrical and plumbing for medical equipment).

A typical cost segregation study on an imaging center can reclassify 25-30% of the building’s cost basis into 5, 7, and 15-year property. On a $3M building, that’s $750,000 to $900,000 of cost that can be depreciated much faster.

The real power comes when you pair this with bonus depreciation. Those reclassified 5, 7, and 15-year assets are eligible for 100% bonus depreciation (or the prevailing rate). This allows you to take a massive, front-loaded deduction in the very first year the building is placed in service, instead of waiting 39 years. This can generate a tax deduction of several hundred thousand dollars in year one, providing a significant cash flow boost.

**The Trap:** A cost segregation study must be performed by a qualified engineering firm. An IRS audit will scrutinize these studies, and a poorly documented or overly aggressive report will be disallowed. Don’t try to save money with a cheap, “cookie-cutter” online service. Use a reputable firm that will stand behind its engineering analysis.

The rise of theranostics is more than a clinical breakthrough; it’s a call to action for nuclear medicine physicians to become architects of their own financial futures. By pairing high-value clinical services with sophisticated ownership and tax-planning structures, you can move beyond the limitations of traditional practice models. The strategies of aggressive depreciation, entity structuring, and real estate optimization are the tools that transform practice revenue into personal wealth. This is the new economics of nuclear medicine.

Free GigHz Tools That Pair With This Article

Three free tools that complement the material above:

• ACR Appropriateness Criteria Lookup — Type an indication or clinical scenario in plain language and get the imaging studies the ACR rates for it, with adult and pediatric radiation levels. Built directly from 297 ACR topics, 1,336 clinical variants, and 15,823 procedure ratings.
• GigHz Imaging Protocol Library — A searchable library of 131 imaging protocols with the physics specs surfaced and the matching ACR Appropriateness Criteria alongside. Plain-English narratives readable in 60 seconds, organized by modality.
• GigHz Radiation Dose Calculator — Pick the imaging studies a patient has had and see total dose in millisieverts (mSv) with comparisons to natural background radiation, transatlantic flights, and chest X-rays. Useful for shared decision-making.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026